ArticleScientific reports2025
Intravenous acellular human amniotic fluid prevents ischemic cardiac remodeling.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Amniotic products are potent immunomodulators used clinically to repair tissue injury. This study sought to determine the impact of acellular human amniotic fluid (hAF) on cardiac remodeling. Amniotic fluid was obtained from volunteer donors at the time of elective caesarean section, proprietarily processed into a sterile filtered acellular hAF, and administered to rats following coronary ligation. Compared to controls, hAF treated animals had a nearly sixfold decrease in both infarct size and fibrosis. Under hypoxic stress, hAF-treated H9C2 cells demonstrated higher cell viability and mitochondrial membrane stability and less apoptosis compared to saline-treated cells. Here we demonstrate that a single intravenous dose of acellular hAF provides functional cardioprotection that is mechanistically associated with cellular tolerance to hypoxic insult likely afforded by the plethora of naturally produced cytokines, chemokines, and immune-modulating proteins present in hAF. The ubiquitous availability of acellular hAF offers promising potential for its use as a cardioprotective adjunct.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.